Comprehensive Characterization of Intraductal Oncocytic Papillary Neoplasm of the Pancreas: a systematic and critical review

Publication date

2024-09

Authors

Paolino, Gaetano
Basturk, Olca
Esposito, Irene
Hong, Seung-Mo
Brosens, Lodewijk AORCID 0000-0003-1341-8994
Tarcan, Zeynep
Wood, Laura D
Gkountakos, Anastasios
Omori, Yuko
Mattiolo, Paola

Editors

Advisors

Supervisors

Document Type

Article

Collections

Open Access logo

License

cc_by

Abstract

Intraductal oncocytic papillary neoplasm (IOPN) of the pancreas is a recently recognized pancreatic tumor. Here, we aimed to determine its most essential features with the systematic review tool. PubMed, Scopus, and Embase were searched for studies reporting data on pancreatic IOPN. The clinicopathologic, immunohistochemical, and molecular data were extracted and summarized. Then, a comparative analysis of the molecular alterations of IOPN with those of pancreatic ductal adenocarcinoma and intraductal papillary mucinous neoplasm from reference cohorts (including The Cancer Genome Atlas) was conducted. The key findings from 414 IOPNs were as follows: 1) The male-to-female ratio was 1.5:1. Pancreatic head was the most common site (131/237; 55.3%), but a diffuse tumor extension involving more than one pancreatic segment was described in about 1 out of 5 cases (49/237; 20.6%). The mean size was 45.5 mm. An associated invasive carcinoma was present in 50% of cases (168/336). In those cases, most tumors were pT1 or pT2 and pN0 (>80%), and vascular invasion was uncommon (20.6%). Regarding survival, more than 90% of patients were alive after surgical resection. 2) Immunohistochemical and molecular features were as follows. The most commonly expressed mucins were MUC5AC (110/112; 98.2%) and MUC6 (78/84; 92.8%). Compared with pancreatic ductal adenocarcinoma and intraductal papillary mucinous neoplasm, the classic pancreatic drivers KRAS, TP53, CDKN2A, SMAD4, and GNAS were less altered in IOPN (P < .01). Moreover, fusions involving PRKACA or PRKACB gene were detected in all of the 68 cases examined, with PRKACB::ATP1B1 being the most common (27/68 cases; 39.7%). These genomic events emerged as an entity-defining molecular alteration of IOPN (P < .01). Thus, such fusions represent a promising biomarker for diagnostic purposes. Recent evidence also suggests their role in influencing the acquisition of oncocytic morphology. IOPN is a distinct pancreatic neoplasm with specific clinicopathologic and molecular features.

Keywords

intraductal, intraductal oncocytic papillary neoplasm, intraductal papillary mucinous neoplasm, oncocytic, oxyphilic, pancreatic cancer, PRKACA, PRKACB, General Medicine, Journal Article, Review

Citation

Paolino, G, Basturk, O, Esposito, I, Hong, S-M, Brosens, L A, Tarcan, Z, Wood, L D, Gkountakos, A, Omori, Y, Mattiolo, P, Ciulla, C, Marchegiani, G, Pea, A, Bevere, M, De Robertis, R, D'Onofrio, M, Salvia, R, Cheng, L, Furukawa, T, Scarpa, A, Adsay, V & Luchini, C 2024, 'Comprehensive Characterization of Intraductal Oncocytic Papillary Neoplasm of the Pancreas : a systematic and critical review', Modern Pathology, vol. 37, no. 9, 100554. https://doi.org/10.1016/j.modpat.2024.100554